Connect with us

Technology

Investors in Common Stock and Certain Debt Securities Offered by Valeant Pharmaceuticals International, Inc. May be Entitled to Payment from an SEC Fair Fund

Published

on

WASHINGTON, Oct. 19, 2024 /CNW/ — The following statement is being issued regarding the Valeant Pharmaceuticals Fair Fund.

UNITED STATES SECURITIES AND
EXCHANGE COMMISSION

 

In the Matter of

 

Valeant Pharmaceuticals International, Inc. n/k/a
Bausch Health Companies Inc.; J. Michael Pearson;
Howard B. Schiller; and Tanya R. Carro, CPA,

 

Respondents.

 

ADMINISTRATIVE PROCEEDING
File Nos. 3-19899, 3-19900, 3-19901, and 3-19902

 

Valeant Pharmaceuticals Fair Fund 

SUMMARY DISTRIBUTION PLAN NOTICE

The United States Securities and Exchange Commission authorized this Notice. 

This is not a solicitation from a lawyer.

 

Who is Eligible to Participate in the Fair Fund?

If you purchased or otherwise acquired Valeant Pharmaceuticals International, Inc. (“Valeant”) common stock between October 20, 2014 and April 28, 2016, inclusive, or certain bonds issued by Valeant identified in Exhibit A of the Corrected Plan of Distribution (the “Plan”) between October 20, 2014 and October 29, 2015, inclusive, you may be entitled to receive a Distribution Payment from the Valeant Pharmaceuticals Fair Fund, created in the captioned proceedings (the “Fair Fund”), subject to other provisions of the Plan. For a complete list of Eligible Valeant Securities, please visit www.ValeantFairFund.com.

The administration of the Fair Fund is governed by the Plan approved by the Commission on August 22, 2024. A copy of the Plan, which contains a description of eligibility and other conditions of participation, is available at www.ValeantFairFund.com.

Determination of Recognized Claims

The amount of compensation shall be determined in accordance with the Plan of Allocation. Each Eligible Claimant’s Recognized Loss is determined by the calculations outlined in the Plan of Allocation. If the Net Available Distribution Fund is less than the sum of the Recognized Losses of all Eligible Claimants, each Eligible Claimant’s distribution amount will equal his, her or its “Pro Rata Percentage” of the Net Available Distribution Fund. If an Eligible Claimant’s Pro Rata Percentage is less than the Minimum Distribution Amount of $10, that Eligible Claimant will be deemed ineligible to receive a Distribution Payment. Further, an Eligible Claimant’s distribution amount will be no larger than his, her, or its Recognized Loss minus the amount of any compensation for the loss that resulted from the conduct described in the Order that was received from another source (e.g., class action settlement), to the extent known by the Fund Administrator (“Prior Recovery”), plus any Reasonable Interest awarded. That is, the distribution amount will be capped at the Recognized Loss less the Prior Recovery, plus any Reasonable Interest awarded.

How to Participate

If you believe you are potentially an Eligible Claimant and would like to participate, you must file your Proof of Claim Form via the online claim filing portal available at www.ValeantFairFund.com on or before the Claims Bar Date referenced below. Alternatively, you may download and complete a paper Claim Form and mail it to the address below. When submitting a claim, you must also include acceptable supporting documentation to confirm your transactions in Eligible Valeant Securities.

Claims Bar Date: January 16, 2025, 11:59 P.M. PST

Website:     

www.ValeantFairFund.com

Email:         

info@ValeantFairFund.com

Phone:       

1-888-890-6712

Address:     

Valeant Pharmaceuticals Fair Fund
c/o Verita Global
Fund Administrator 
P.O. Box 301133
Los Angeles, CA 90030-1133

 

Questions?

This Notice provides only summary information regarding the Valeant Fair Fund. We strongly recommend that you consult the documentation found at www.ValeantFairFund.com in its entirety.

Media Contact: 1-888-890-6712; info@ValeantFairFund.com

View original content:https://www.prnewswire.com/news-releases/investors-in-common-stock-and-certain-debt-securities-offered-by-valeant-pharmaceuticals-international-inc-may-be-entitled-to-payment-from-an-sec-fair-fund-302278342.html

SOURCE Valeant Fair Fund

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Orbita Appoints Jeff Taylor as New Chief Executive Officer (CEO)

Published

on

By

Orbita, a leading innovator in AI-powered automation to optimize patient workflows for specialty care, announces the appointment of industry veteran Jeff Taylor to serve as its new Chief Executive Officer.

BOSTON, Oct. 19, 2024 /PRNewswire-PRWeb/ — Orbita, a leading innovator in AI-powered automation to optimize specialty patient care workflows, is pleased to announce the appointment of Jeff Taylor as its new CEO.

“Orbita is on the cutting edge of AI innovation in healthcare…I look forward to working with this talented team to drive our mission forward.” – Jeff Taylor, CEO

With more than 20 years of leadership in healthcare IT and business solutions, Jeff Taylor brings a wealth of experience to Orbita AI. His expertise in driving growth, operational excellence, and organizational transformation positions him to lead Orbita into its next phase of expansion and innovation.

Prior to joining Orbita, Taylor served as the CEO of Innovative Consulting Group (ICG), where he spearheaded the company’s mission to deliver IT-based business and clinical optimization solutions across healthcare networks nationwide. With over 400 customers across the country, Jeff helped ICG to establishing itself as a trusted partner for healthcare organizations seeking cutting-edge technological improvements.

Before his tenure at ICG, Taylor held the role of Chief Revenue Officer at MEDLAB, a national leader in medical laboratory services. At MEDLAB, he successfully led the company’s sales, marketing, and acquisition strategies, playing a key role in its rapid expansion and market growth.

Commenting on his new role, Taylor said, “I’m excited to join Orbita at such a pivotal moment in its journey. Orbita is on the cutting edge of AI innovation in healthcare, and I look forward to working with this talented team to drive our mission forward and explore new opportunities for growth.”

About Orbita

Orbita builds AI-powered automation solutions that optimize clinical workflows, improve patient outcomes, and reduce costs for health systems and specialty practices. By safely applying advanced machine learning, natural language processing, and generative AI, Orbita provides transformative technologies and solutions to optimize patient and provider experiences.

Media Contact

Nathan Treloar, Orbita, Inc., 1 4133742431, nate@orbita.ai, https://www.orbita.ai/

LinkedIn

View original content to download multimedia:https://www.prweb.com/releases/orbita-appoints-jeff-taylor-as-new-chief-executive-officer-ceo-302280450.html

SOURCE Orbita, Inc.

Continue Reading

Technology

Optimizing Remittance Flows: Central Bank of Nigeria to Participate in High-Level Forum in Houston, Texas

Published

on

By

In collaboration with NIBSS, Nigerian banks, and IMTOs, the CBN seeks to deepen engagement with the Nigerian diaspora community

HOUSTON, Oct. 19, 2024 /PRNewswire/ — The Central Bank of Nigeria (CBN), in collaboration with the Nigeria Inter-Bank Settlement System (NIBSS), major Nigerian banking institutions, and International Money Transfer Operators (IMTOs), will participate in a pivotal forum titled Optimizing Remittances to Nigeria: A Vision for the Future” in Houston, Texas, on October 20, 2024. This high-level event brings together critical stakeholders in the remittance ecosystem to engage with the Nigerian diaspora community on opportunities to enhance remittance flows and strengthen Nigeria’s financial sector.

CBN’s broader engagements alongside the IMF & World Bank Annual Meetings, highlights the Bank’s commitment to Nigerians.

As part of the CBN’s broader engagements alongside the IMF & World Bank Annual Meetings, this forum highlights the Bank’s commitment to building stronger financial ties with Nigerians abroad. It is part of a series of engagements the Bank will participate in over the coming months. In an era of bold reforms, the CBN is prioritizing strategies to leverage diaspora remittances as a catalyst for inclusive economic growth, financial inclusion, and overall national development.

Houston, a city renowned for having the largest Nigerian diaspora population in the United States, plays a significant role in shaping remittance inflows to Nigeria. The city’s vibrant Nigerian community has contributed immensely to both the local economy in Houston and to Nigeria’s economic stability through remittances. As a major contributor to Nigeria’s annual remittance inflows, estimated by the World Bank at $20.5 billion over the last decade, the Houston diaspora community serves as a critical partner in Nigeria’s economic growth.

The event will feature contributions from senior bank executives, policy discussions on optimizing remittance channels, and practical approaches for further leveraging these flows to support the development of Nigeria. Networking opportunities with key leaders from Nigeria’s financial industry will also be available.

“This forum represents a unique opportunity to recognize and enhance the contributions of the Nigerian diaspora, particularly the community in Houston, who continue to play an essential role in shaping our country’s economic future,” said CBN Governor Olayemi Cardoso. “Through strategic partnerships with key stakeholders such as NIBSS, our banking institutions, and IMTOs, we aim to create a future where remittance flows can be more impactful for both Nigeria and its diaspora.”

Partnering institutions include NIBSS, Providus Bank, Fidelity Bank, First City Monument Bank, First Bank of Nigeria, Zenith Bank, and United Bank for Africa.

For further information or participation inquiries, please contact Linda Anukwuem at linda@aixfirm.com.

www.aixfirm.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/optimizing-remittance-flows-central-bank-of-nigeria-to-participate-in-high-level-forum-in-houston-texas-302281017.html

SOURCE Central Bank of Nigeria

Continue Reading

Technology

Kaia Health Appoints Adam Pellegrini as Global CEO And Launches The First Digital Pulmonary Rehab Program In Partnership With The COPD Foundation

Published

on

By

NEW YORK, Oct. 19, 2024 /PRNewswire/ — Kaia Health (Kaia), a leading digital health company, announces the appointment of Adam Pellegrini as its new Chief Executive Officer. Pellegrini brings a wealth of experience in digital health and a proven track record of driving innovation and growth. His appointment coincides with the highly anticipated US launch of Kaia Breathe, a digital-first pulmonary rehab program designed to support patients with COPD and other respiratory diseases.

Kaia Health Appoints Adam Pellegrini as Global CEO; Launches First Digital Pulmonary Rehab Program With COPD Foundation

Pellegrini brings more than two decades of experience in digital health to Kaia, having held executive roles at industry leaders such as Microsoft, Fitbit, Walgreens, CVS Health, and most recently, Jasper Health. His strategic vision and deep expertise in consumer behavior within the digital health landscape position him as the ideal leader to guide Kaia Health through its next phase of growth.

As part of the launch of Kaia Breathe, Kaia is proud to announce a partnership with the COPD Foundation, joining them on their mission to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease.

“More than 30 million people in the United States have COPD, and many struggle to manage their condition. Kaia Health’s digital-first rehabilitation model is already improving the lives of thousands, and I see a similar opportunity in pulmonary rehab to ease the disease burden for COPD patients and their caregivers,” said Pellegrini. “Today, in partnership with the COPD Foundation, we are launching Kaia Breathe, a digital solution that delivers consistent, clinically impactful therapy at scale coupled with engaging, habit-building technology”

“Innovative technologies like Kaia Breathe are transforming the landscape of pulmonary rehabilitation, providing individuals with greater access to personalized care that meets their unique needs,” said Jean Wright, M.D., MBA, CEO of the COPD Foundation. “By combining our expertise in COPD and Kaia Health’s digital solutions, this collaboration aims to make a lasting impact on the lives of millions living with chronic lung diseases.”

Kaia Breathe marks a significant advancement in managing chronic respiratory conditions through pulmonary rehabilitation. The program delivers personalized exercise therapy and condition education, supported by coaches and artificial intelligence motion tracking technology, enabling patients to manage their symptoms more effectively and improve their quality of life. With the US launch of this solution, Kaia Health aims to empower millions of COPD patients to manage their health and well-being from the comfort of their homes.

Pellegrini will officially launch Kaia Breathe at the HLTH conference in Las Vegas this week.

To learn more about Kaia Health, please visit kaiahealth.com. For more information about the COPD Foundation, visit copdfoundation.org.

About Kaia Health:
Kaia Health is the world’s largest digital therapeutics company on a mission to empower millions of people to live their healthiest lives. Kaia Health partners with leading health plans, employers, and providers, covering nearly 65 million lives around the world. Kaia’s evidence-based treatments, covering a range of conditions, including MSK and COPD, are powered by proprietary AI, motion analysis technology, and clinical expertise. Kaia’s app is designed to work on your smartphone or tablet – delivering the most accessible, effective, and equitable experience available. Across 20 clinical trials, Kaia Health has demonstrated effectiveness and safety on par with traditional care with as much as 80% reduction in cost, as recognized by the Program Validation from the independent Validation Institute.

About the COPD Foundation:
The COPD Foundation is a nonprofit organization whose mission is to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease. The Foundation does this through scientific research, education, advocacy, and awareness to prevent disease, slow progression, and find a cure. For more information, visit copdfoundation.org, or follow us on Twitter and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/kaia-health-appoints-adam-pellegrini-as-global-ceo-and-launches-the-first-digital-pulmonary-rehab-program-in-partnership-with-the-copd-foundation-302280961.html

SOURCE Kaia Health

Continue Reading

Trending